Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Digestive Diseases and Sciences
Erschienen in: Digestive Diseases and Sciences 4/2011

01.04.2011 | Original Article

Pioglitazone: A Promising Therapeutic Tool in Sodium Taurocholate-Induced Severe Acute Pancreatitis

verfasst von: Ping Xu, Kai Xu, Jing Wang, Jin-Ping Jiang, Ling-Quan Chen

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Studies suggest that peroxisome proliferator-activated receptor γ(PPARγ) ligands may represent a therapeutic option in acute pancreatitis, yet most of them have been prophylactic administrated.

Aims

To evaluate the therapeutic effect of pioglitazone in rats with severe acute pancreatitis induced by sodium taurocholate.

Methods

Severe acute pancreatitis (SAP) was induced in male Sprague–Dawley rats by the retrograde injection of 5% sodium taurocholate into the pancreatic duct. After SAP was induced, pioglitazone was injected intraperitoneally and its role on the severity of inflammatory response and pancreatic injury was investigated. Amylase activity, inflammatory cytokines production, pathological changes of pancreas, PPARγ mRNA expression, and the survival rate were examined.

Results

Treatment with pioglitazone decreased the level of amylase activity, proinflammatory factors IL-6 and TNF-α, ameliorated pancreatic histological score, and upregulated the expression of PPARγ mRNA. The survival rate in the early stage of severe acute pancreatitis was also improved.

Conclusions

Pioglitazone can be used as a therapeutic drug and relieve the damages caused by SAP, which suggests PPARγ ligand-pioglitazone offers a potent approach for the treatment of severe acute pancreatitis.
Literatur
1.
Chiang DT, Anozie A, Fleming WR, et al. Comparative study on acute pancreatitis management. ANZ J Surg. 2004;74(4):218–221.PubMedCrossRef
2.
Vamecq J, Latruffe N. Medical significance of peroxisome proliferators-activated receptors. Lancet. 1999;354(9173):141–148.PubMedCrossRef
3.
Rahimian R, Masih-Khan E, Lo M, et al. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem. 2001;224(1–2):29–37.PubMedCrossRef
4.
Yin R, Dong YG, Li HL. PPAR gamma phosphorylation mediated by JNK MAPK: a potential role in macrophage-derived foam cell formation. Acta Pharmacol Sin. 2006;27(9):1146–1152.PubMedCrossRef
5.
Wang AC, Dai X, Luu B, et al. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol. 2001;24(6):688–693.PubMed
6.
Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology. 2003;124(5):1315–1324.PubMedCrossRef
7.
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391(6662):82–86.PubMedCrossRef
8.
Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391(6662):79–82.PubMedCrossRef
9.
Zingarelli B, Sheehan M, Hake PW, et al. Peroxisome proliferator activated receptor-gamma ligands, 15-deoxy-Delta(12, 14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol. 2003;171(12):6827–6837.PubMed
10.
Enomoto N, Takei Y, Hirose M, et al. Prevention of ethanol-induced liver injury in rats by an agonist of peroxisome proliferator-activated receptor-gamma, pioglitazone. J Pharmacol Exp Ther. 2003;306(3):846–854.PubMedCrossRef
11.
Konturek PC, Dembinski A, Warzecha Z, et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulean-induced pancreatitis. World J Gastroenterol. 2005;11(40):6322–6329.PubMed
12.
Hughes CB, Grewal HP, Gaber LW, et al. Anti-TNF alpha therapy improves survival and ameliorates the pathophysiologic saquelae in acute pancreatitis in the rat. Am J Surg. 1996;171(2):274–280.PubMedCrossRef
13.
Schmidt J, Rattner DW, Lewandrowski K, et al. A better model of acute pancreatitis for evaluating therapy. Ann Surg. 1992;215(1):44–56.PubMedCrossRef
14.
Xu P, Zhou XJ, Chen LQ, et al. Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis. World J Gastroenterol. 2007;13(13):1983–1988.PubMed
15.
Folch-Puy E, Granell S, Iovanna JL, et al. Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats. World J Gastroenterol. 2006;12(40):6458–6463.PubMed
16.
Hashimoto K, Ethridge RT, Saito H, et al. The PPARgamma ligand, 15d-PGJ2, attenuates the severity of cerulein-induced acute pancreatitis. Pancreas. 2003;27(1):58–66.PubMedCrossRef
17.
Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein. Intensive Care Med. 2004;30(5):951–956.PubMedCrossRef
18.
Chen C, Xu S, Wang WX, et al. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury. Arch Med Res. 2009;40(2):79–88.PubMedCrossRef
19.
De Beaux AC, Fearon KC. Circulating endotoxin, tumor necrosis factor-alpha, and their natural antagonists in the pathophysiology of acute pancreatitis. Scand J Gastroenterol. 1996;31(219):43–46.CrossRef
20.
De Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg. 1996;83(3):349–353.PubMedCrossRef
21.
Denham W, Yang J, Fink G, et al. Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pancreatitis. Gastroenterology. 1997;113(5):1741–1746.PubMedCrossRef
22.
Rongione AJ, Kusske AM, Kwan K, et al. Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology. 1997;112(3):960–967.PubMedCrossRef
23.
Laveda R, Martinez J, Munoz C, et al. Different profile of cytokine synthesis according to the severity of acute pancreatitis. World J Gastroenterol. 2005;11(34):5309–5313.PubMed
24.
Van Laethem JL, Eskinazi R, Louis H, et al. Multisystemic production of interleukin 10 limits the severity of acute pancreatitis in mice. Gut. 1998;43(3):408–413.PubMedCrossRef
25.
Giri S, Rattan R, Singh AK, et al. The 15-deoxy-delta 12, 14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol. 2004;173(8):5196–5208.PubMed
26.
Li M, Pascual G, Glass CK. Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol Cell Biol. 2000;20(13):4699–4707.PubMedCrossRef
27.
Feingold K, Kim MS, Shigenaga J, et al. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response. Am J Physiol Endocrinol Metab. 2004;286(2):E201–E207.PubMedCrossRef
28.
Hill MR, Young MD, McCurdy CM, et al. Decreased expression of murine PPARgamma in adipose tissue during endotoxemia. Endocrinology. 1997;138(7):3073–3076.PubMedCrossRef
29.
Tanaka T, Itoh H, Doi K, et al. Down regulation of peroxisome proliferator-activated receptorgamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia. 1999;42(6):702–710.PubMedCrossRef
30.
Rollins MD, Sudarshan S, Firpo MA, et al. Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis. J Gastrointest Surg. 2006;10(8):1120–1130.PubMedCrossRef
Metadaten
Titel
Pioglitazone: A Promising Therapeutic Tool in Sodium Taurocholate-Induced Severe Acute Pancreatitis
verfasst von
Ping Xu
Kai Xu
Jing Wang
Jin-Ping Jiang
Ling-Quan Chen
Publikationsdatum
01.04.2011
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2011
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1393-0

Weitere Artikel der Ausgabe 4/2011

Digestive Diseases and Sciences 4/2011 Zur Ausgabe

Original Article

Adult Patients with Eosinophilic Esophagitis Do Not Show an Increased Frequency of the HLA-DQ2/DQ8 Genotypes Predisposing to Celiac Disease

Review

Unusual Case of Small Cell Gastric Carcinoma: Case Report and Literature Review

Original Article

Daily Ciprofloxacin Treatment for Patients with Advanced Liver Disease Awaiting Liver Transplantation Reduces Hospitalizations

Erratum

Erratum to: Site Specific Delivery of Microencapsulated Fish Oil to the Gastrointestinal Tract of the Rat

Original Article

Does Grading the Severity of Gastroparesis Based on Scintigraphic Gastric Emptying Predict the Treatment Outcome of Patients with Gastroparesis?

Original Article

HCV-Related Proteins Activate Kupffer Cells Isolated from Human Liver Tissues

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise